On April 28, 2026, the Canadian healthcare landscape changed forever.
In a historic move, Health Canada officially authorized the first generic version of injectable semaglutide (the active ingredient in Ozempic®) for sale. This makes Canada the first G7 nation to greenlight a generic version of this medication.
At Felix, we believe this isn’t just a win for the pharmaceutical industry, it’s a long-overdue win for the more than 10 million Canadians who have, until now, been priced out of the care they deserve.
Expanding access with reduced pricing
For too long, the cost of these treatments has placed them out of reach for many Canadians who could benefit from them the most. While clinical evidence supporting these medications has grown, the high price point has often stood in the way of patients accessing the available support.
This barrier hasn’t been a lack of will, it’s been a lack of affordability.
At $100/month, nearly six times more Canadians say they’d consider treatments compared to $400/month, according to a study we recently conducted with Angus Reid.*
In Canada, the government and generic manufacturers have a pricing framework that lowers the price of generics as more of them enter the market:
| Number of generics | Est. generic price (vs. brand)* |
| 1 generic available | $240 per pen (~75% of brand price) |
| 2 generics available | $160 per pen (~50% of brand price) |
| 3 or more generics available | $112 per pen (~35% of brand price) |
*Based on the current brand price of $320 per pen.
This significantly reduced price point would allow approximately 29% of eligible Canadians to finally start treatment.
Most Canadians are in the dark about generic semaglutide
Even with the magnitude of this news, our research found a staggering lack of awareness in Canada as a mere 23% of Canadians knew generics were on the horizon.
Despite the information gap around generics, our study indicated that 97% of Canadians had heard of these medications, but only 31% had ever seriously considered using one.
The lack of awareness around generics is about more than just a lower price point; it’s a reflection of how little information is available regarding this particular science. At Felix, we believe that when patients have better access to information, they have better outcomes.
When is it all happening?
Now that the first generic manufacturers (Dr Reddy’s and Apotex) have received their Notice of Compliance from Health Canada, the focus shifts to the physical rollout of the generic medication. We anticipate that generic semaglutide could become available in Canada as early as June 2026.
We are working closely with our partners to ensure that as soon as supply is ready, our patients will be informed.
To stay up to date with the rollout of generic semaglutide, join our waitlist.
Where you get care matters
As the “dam breaks” and the market floods with new, more affordable options, the space is bound to get crowded. While affordability is a major victory for patients, where you receive your care is just as important. Your health and well-being deserves a partner who prioritizes clinical integrity as much as accessibility.
This is where Felix stands apart.
We are Canada’s largest online health platform, supervised by an experienced network of licensed healthcare practitioners. We’ve built the most comprehensive program designed by Canada’s leading specialists in the field to maximize long-term outcomes, featuring tools like weekly dose trackers while providing access to clinical support through text.
As prices drop, our commitment to safety remains consistent. Our research shows a significant generational gap, with those aged 18-34 being the least likely to consult a professional. Whether you’re just starting your journey or have been managing your health for years, you deserve a partner who prioritizes long-term wellness over a transaction.
A win for 10 million Canadians
Behind every headline and every clinical stat is a person. It’s the parent who wants to be there for their kids; the professional managing demands of their career; and the Canadian who deserves more than over simplified answers.
With the arrival of generic semaglutide in Canada, science-backed care is no longer a privilege for the few. It is now an option for the many.
A new era of healthcare has arrived. And at Felix, we’re proud to be the ones opening the door.
–
*This study was commissioned by Felix Health and conducted by Angus Reid. The survey was in-field from December 11–15, 2025. For comparison purposes, a probability sample of this size would yield a margin of error of ±3%, 19 times out of 20.
